John C. Byrd, MD - The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

Go online to PeerView.com/VXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Get the latest on BTK inhibitor strategies in CLL in this PeerView Clinical Consults video recorded at the Annual Hematology Meeting. Once inside, you’ll be able to engage with expert panel discussions designed to provide guidance for using BTK inhibitor therapy in CLL based on longer follow-up data from phase 3 trials and head-to-head safety evidence. Throughout, the experts share and comment on real-world cases that reflect modern, customized therapy selection based on prognostic factors, safety and selectivity differences between available agents, and efficacy in pretreated disease. Don’t miss this opportunity to learn about customizing BTKi therapy from our experts, and get your CME/MOC credit hours! Upon completion of this activity, participants should be better able to: Describe current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines on BTK inhibitor efficacy, safety, and selectivity differences, including as single-agent approaches or as part of novel combinations; Select personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Recommend sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Develop a management plan for adverse events associated with first- and second-generation BTK inhibitors used to treat CLL